The Horizen Platform
01
The Horizen Platform
Providing clinicians
critical visibility
into cancer tumor biology
CellaraRx’s Horizen platform helps clinicians and drug developers identify which patients are most likely to respond to cancer treatments in clinical trials - before enrollment.
This improves patient selection and helps effective therapies reach FDA approval.
By combining single-cell RNA sequencing, digital pathology, and AI, Horizen reveals tumor features that standard methods cannot see.
02
How Horizen Works
01
Inputs
Before a patient enters a clinical trial, Horizen integrates multiple biological data sources:
✔ Single-cell RNA sequencing
✔ Digital pathology imaging
✔ Multi-omics tumor data
This allows Horizen to analyze tumors at the level of individual cells and their spatial organization within tissue.
02
Visibility
Horizen provides insights that are often invisible to traditional genomic approaches:
✔ Which cancer cells may already be resistant to a therapy
✔ Where those cells are located within the tumor
✔ Whether the drug can effectively reach its intended targets
These insights help determine whether a patient’s tumor is biologically compatible with a therapy.
03
Outcomes
By revealing resistance mechanisms and tissue accessibility before enrollment, Horizen enables:
✔ More precise patient stratification for clinical trials
✔ Improved trial design and success rates
✔ Reduced late-stage trial failures
Ultimately, Horizen helps ensure that the right patients receive the right therapies.